Browsing Tag
COPD
23 posts
GSK wins China approval for Trelegy Ellipta in asthma, expanding respiratory market reach
Trelegy Ellipta is now approved for asthma in China, giving GSK dual coverage in COPD and asthma. Find out what this means for respiratory market dynamics.
GSK wins approval in China for Nucala in eosinophilic COPD, expanding respiratory biologics reach
Find out how GSK’s Nucala just became the first biologic approved for eosinophilic COPD in China—and what it means for the future of respiratory care.
GSK dodges tariffs with a massive pricing pivot—but what’s the catch?
GlaxoSmithKline cuts drug prices in the U.S. and secures tariff relief under a new federal deal. Find out what this means for pharma's future pricing playbook.
Mabwell’s anti-ST2 antibody enters U.S. trials: Can 9MW1911 reshape immunotherapy for COPD?
Mabwell’s anti-ST2 antibody 9MW1911 enters U.S. trials after strong COPD data in China. Find out what this could mean for immunotherapy's future in COPD.
Is Merck building the next great cardiometabolic franchise? A closer look at WINREVAIR, enlicitide and Ohtuvayre
See how Merck is building a cardiometabolic growth engine with WINREVAIR, enlicitide and Ohtuvayre—and what it means for investors.
Why fall is becoming a difficult season for people with asthma and COPD—and what VARON suggests
Fall air can trigger breathing issues. Discover how VARON oxygen solutions support respiratory wellness at home and on the go this season.
AstraZeneca’s Fasenra misses primary endpoint in COPD trial but keeps investor confidence alive
AstraZeneca’s Fasenra failed to hit its COPD trial endpoint, but stock rose 0.44% as investors bet on pipeline strength and respiratory growth.
Why Shilpa’s bet on Alveolus Bio may reshape the future of pulmonary biologics
Shilpa Medicare leads funding round in Alveolus Bio to accelerate Phase 2 COPD trials and first-in-human studies for novel inhaled therapeutics.
Can Merck turn Ohtuvayre into a global COPD blockbuster? A look at pricing, access, and lifecycle strategy
Can Merck scale Ohtuvayre into a global COPD blockbuster? Explore its pricing strategy, global access plans, and lifecycle ambitions in this in-depth analysis.
Merck to acquire Verona Pharma for $10bn, securing Ohtuvayre COPD therapy
Verona Pharma stock jumps 20% as Merck announces $10B acquisition to boost its COPD pipeline with first-in-class therapy Ohtuvayre. Read full analysis.